Genesis IBRC Share Price Today | Stock Price & Genesis IBRC Share Screener
As of April 20, 2026, the live Genesis IBRC share price (BSE: GENESIS) is ₹85.36, up 4.99% from the previous close, with shares trading between ₹85.36 and ₹85.36 in today's trading session, and a 52-week range of ₹62.55–₹184.90. Check GENESIS price range for the annual price range and momentum. Use the Genesis IBRC stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Genesis IBRC opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Genesis IBRC Share Price Chart
Track the current stock price of Genesis IBRC with an interactive chart. Analyse GENESIS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Genesis IBRC stock quote in one place.
The quote of ₹85.36 sits between the 52-week low of ₹62.55 and the 52-week high of ₹184.90, and the latest session moved 4.99% from the previous close.
Genesis IBRC Company Profile - Fundamental Screener
Screen Genesis IBRC company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GENESIS shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Biotechnology industry, and it trades under ISIN INE194N01016.
Company Details
Classification
Identifiers and Leadership
Genesis IBRC Balance Sheet Screener
Screen GENESIS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2018, total assets were ₹12.
Latest statistics put total assets at ₹12 and shareholder funds at ₹10, with a leverage ratio of 0.15.
| Item | 2018 |
|---|---|
Assets |
|
| Total Assets | 12 |
| Current Assets | 7 |
| Fixed Assets | 2 |
Liabilities |
|
| Total Liabilities | 0 |
| Current Liabilities | 0 |
| Non-Current Liabilities | 0 |
Shareholders' Equity |
|
| Total Equity | 10 |
| Share Capital | 13 |
| Reserves & Surplus | -3 |
Genesis IBRC Income Statement Screener - Profit & Revenue Analysis
Screen Genesis IBRC income statement and profit fundamentals. Analyze GENESIS quarterly results. Genesis IBRC reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹0 and net profit was ₹0.
In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2018-March, shows revenue of ₹4 and net profit of ₹0.
| Item | None-None | 2018-March |
|---|---|---|
Revenue and Expenses | ||
| Revenue | 0 | 4 |
| Expenses | 0 | 4 |
Operating Costs and Margins | ||
| EBITDA | 0 | 0 |
| Operating Profit % | 0.00% | 4.00% |
| Depreciation | 0 | 0 |
| Interest | 0 | 0 |
Profit and Earnings | ||
| Profit Before Tax | 0 | 0 |
| Tax | 0 | 0 |
| Net Profit | 0 | 0 |
| EPS | 0.00 | -0.03 |
Genesis IBRC Cash Flow Screener - Liquidity Fundamentals
Screen GENESIS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2018-March, operating activities generated ₹2.
Over the same period, investing activities used ₹5 and financing activities provided ₹3.
| Item | 2018-March |
|---|---|
Cash from Operations and Investing | |
| Operating Activities | 2 |
| Investing Activities | -5 |
Financing and Net Cash | |
| Financing Activities | 3 |
| Net Cash Flow | 0 |
Genesis IBRC Shareholding Pattern Screener
See Genesis IBRC shareholding pattern with promoter, FII, and DII holdings. Check Genesis IBRC promoter holding and ownership changes for GENESIS on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Apr, promoters held 74.35%, foreign institutions 0.00%, domestic institutions 0.00% and the public 9.19%, spread across 1,947 shareholders.
The shareholder count was 1,947 in 2026-Apr, compared with 1,747 in 2025-Mar.
| Item | 2026-Apr | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 74.35% | 11.33% | 11.33% | 11.33% | 11.33% | 11.33% | 11.33% | 11.33% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 9.19% | 32.00% | 32.00% | 32.00% | 25.08% | 49.31% | 49.31% | 49.31% |
| Other Holding | 16.46% | 56.66% | 56.66% | 56.66% | 63.59% | 39.36% | 39.36% | 39.36% |
| Shareholder Count | 1,947 | 1,747 | 1,731 | 1,736 | 1,855 | 1,749 | 1,750 | 1,751 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Genesis IBRC. Genesis IBRC dividend yield can be compared with peers and other stocks in the market.
Genesis IBRC Stock Index Membership - Nifty & Sensex
See which indices include Genesis IBRC stock. Check GENESIS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Genesis IBRC Market Events Screener - Corporate Actions
Get Genesis IBRC corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Genesis IBRC stock events that may affect GENESIS share price, along with derivatives, futures and options activity and sector gainers.
9 corporate actions are listed, the most recent entry being Annual General Meeting dated .
It is followed by Annual General Meeting dated and Quarterly Result Announcement dated February 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 4.97% | ||
| Annual General Meeting | NA | 79.36% | ||
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -14.24% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 3.95% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 15.73% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 0.00% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | 0.00% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 4.98% |
| 2018-01-12 | 2018-01-12 | Change Of Name | NA | - |
Genesis IBRC Competitors Screener - Peer Stocks Comparison
Screen GENESIS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 6 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Anthem Biosciences | 40,626 | 83.45 | 1,930 | 30.15% | 451 | 62.37 |
| Advanced Enzyme Tech | 3,375 | 22.22 | 670 | 1.44% | 134 | 64.81 |
| Genesis IBRC | 386 | -1626.00 | 4 | % | 0 | 41.47 |
| Vivo Bio Tech | 64 | 14.36 | 52 | 13.19% | 7 | 67.76 |
| Shree Ganesh Bio-Tech | 27 | -69.00 | 24 | 14.55% | 0 | 68.72 |
| Genomic Valley Biotech | 9 | -190.00 | 1 | 300.00% | 0 | 54.08 |
Genesis IBRC Company Announcements - News & Reports Screener
Screen GENESIS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated April 24, 2026.
The next most recent announcements are dated April 8, 2026 and April 8, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-04-24 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-08 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-08 | Announcement under Regulation 30 (LODR)-Change in Corporate Office Address | - |
| 2026-04-08 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-04-08 | Board Meeting Outcome for Outcome Of Board Meeting For Appointment Of Company Secretary Compliance Officer And KMP. Also For Situation Of Corporate Office And Keeping Books Of Accounts At The Place Other Than Registered Office. | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-30 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-30 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-26 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-03-13 | The Company Has Received In-Principle Approval From BSE Limited For Issue Of Equity Shares On Preferential Basis. | - |
| 2026-03-12 | Announcement under Regulation 30 (LODR)-Change of Company Name | - |
| 2026-03-06 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-03-06 | Adoption Of New Line Of Business By The Company. | - |
| 2026-03-06 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | - |
| 2026-03-06 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-02-14 | Results For The Quarter Ended On December 31 2025. | - |
| 2026-02-14 | Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday February 14 2026 In Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 | - |
| 2026-02-11 | Board Meeting Intimation for Approving Results For The Quarter Ended On December 31 2025 And Other Matters. | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹85.36, within a 52-week range of ₹62.55 to ₹184.90. The P/B ratio is 9.06. Market capitalisation stands at ₹386.27 Cr. The company operates in the Healthcare sector, in the Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on April 27, 2026. This page covers 1 balance sheet periods, 2 income statement periods, 1 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.